420 with CNW — Trial Suggests Marijuana Could Replace Opioids in Pain Management
As more states have opted to end cannabis prohibition and launch legal cannabis markets, there has been a growing body of literature indicating that the controversial plant can be effective against a variety of medical issues. Several studies have found that marijuana can be used to treat chronic pain, and plenty of people are already using the controversial plant as an alternative to pharmaceutical pain medications.
Now researchers currently working on a clinical trial to see whether cannabis can be used as an alternative to opioids in pain management have revealed that the pilot phase had “very promising” results. Run by Labat Africa, an investment holding company that trades on both the Frankfurt and JSE exchanges, the Pharma Ethics Observational Study will involve some 1,000 individuals who have been using opioids to manage chronic pain for at least three months.
In a notice to shareholders, Labat Africa said the opioid painkillers that were previously used by the participants included codeine, morphine and pethidine. Lead researcher Dr. Shiksa Gallow says the trials have been groundbreaking in giving much-needed insight between patient outcomes and marijuana genetics. Furthermore, the trials have provided enough evidence to show that cannabis can be used as an alternative to opioids when it comes to chronic pain management.
Gallow states that 98% of the study participants felt some sort of chronic pain relief after using cannabis. The researchers were even able to wean the patients off their opioid-based treatments, fixing an issue that plagues most patients that suffer from chronic pain conditions: opioid dependency. Gallow notes that participants under 55 years of age preferred to smoke the marijuana while those over 55 preferred the oil.
Unsurprisingly, the patients who smoked felt more immediate relief while those who used the oil had to wait for some time for the substance to take effect. Gallows states that once the researchers achieve the required sample size and collect all the relevant data, they will publish their findings. In the meantime, the research team has been able to extend the study for another year to allow them to recruit more participants.
The team is using cannabis strains, such as Exodus and Tallyman, that tend to work better against chronic pain conditions. According to Labat Africa, the team is planning to introduce the 9 Pound Hammer strain as it has high levels of THC, CBG and terpenes, such as myrcene and caryophyllene. Labat sources its cannabis strains from its Sweetwaters Aquaponics facility in the Eastern Cape.
It would be interesting to see how those premium cannabis strains would perform when grown in the micro gardens engineered by Advanced Container Technologies Inc. (OTC: ACTX) to maximize plant performance.
NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
As more states have opted to end cannabis prohibition and launch legal cannabis markets, there has been a growing body of literature indicating that the controversial plant can be effective against a variety of medical issues. Several studies have found that marijuana can be used to treat chronic pain, and plenty of people are already using the controversial plant as an alternative to pharmaceutical pain medications.
Now researchers currently working on a clinical trial to see whether cannabis can be used as an alternative to opioids in pain management have revealed that the pilot phase had “very promising” results. Run by Labat Africa, an investment holding company that trades on both the Frankfurt and JSE exchanges, the Pharma Ethics Observational Study will involve some 1,000 individuals who have been using opioids to manage chronic pain for at least three months.
In a notice to shareholders, Labat Africa said the opioid painkillers that were previously used by the participants included codeine, morphine and pethidine. Lead researcher Dr. Shiksa Gallow says the trials have been groundbreaking in giving much-needed insight between patient outcomes and marijuana genetics. Furthermore, the trials have provided enough evidence to show that cannabis can be used as an alternative to opioids when it comes to chronic pain management.
Gallow states that 98% of the study participants felt some sort of chronic pain relief after using cannabis. The researchers were even able to wean the patients off their opioid-based treatments, fixing an issue that plagues most patients that suffer from chronic pain conditions: opioid dependency. Gallow notes that participants under 55 years of age preferred to smoke the marijuana while those over 55 preferred the oil.
Unsurprisingly, the patients who smoked felt more immediate relief while those who used the oil had to wait for some time for the substance to take effect. Gallows states that once the researchers achieve the required sample size and collect all the relevant data, they will publish their findings. In the meantime, the research team has been able to extend the study for another year to allow them to recruit more participants.
The team is using cannabis strains, such as Exodus and Tallyman, that tend to work better against chronic pain conditions. According to Labat Africa, the team is planning to introduce the 9 Pound Hammer strain as it has high levels of THC, CBG and terpenes, such as myrcene and caryophyllene. Labat sources its cannabis strains from its Sweetwaters Aquaponics facility in the Eastern Cape.
It would be interesting to see how those premium cannabis strains would perform when grown in the micro gardens engineered by Advanced Container Technologies Inc. (OTC: ACTX) to maximize plant performance.
NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
